Relmada Therapeutics (RLMD) Tops Q1 EPS by 26c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.72), $0.26 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'
• Nvidia and Broadcom earnings: TD Cowen says earnings won’t settle big questions